MEDITE
One-Stop Shop for Cancer Diagnostics

The World Health Organization’s latest World Cancer Report states that global cancer burden has risen to 18.1 million new cases in addition to the 9.6 million deaths during the year. At least one out of four people have lost someone close or somebody that they know, to this dreaded disease. In a majority of cases, the detection happens in the last few stages leaving little or no scope for chances of recovery. The delay in detection combined with the numerous tests that come at a high price, has led to an alarming increase in cancer rates.

MEDITE, a medical technology company specializing in the development of medical devices and consumables for the detection, analysis, and diagnosis of cancer and related diseases is bringing in exceptional solutions to this perturbing situation. Their team of highly qualified researchers and engineers are working toward the research and development of products that help in the early and more accurate detection and monitoring of cancer or pre-cancerous conditions. MEDITE’s innovative products are emerging as a disruptive force in the global histology and cytology cancer detection marketplace.

Starting from the tissue biopsy of the cells to the finished microscopic slide, MEDITE’s product line covers the entire laboratory process making it a one-stop supplier in the field of liquid-based cytology and for laboratories in relation to anatomic pathology. This one-stop feature has enticed several clients in the U.S. market that includes several multi-billion dollar healthcare suppliers, anatomic pathology companies, and some of the largest hospital group purchasing organizations.

Following its merger with CytoCore, an American public company whose scientific advances are in synergy with MEDITE’s product lines, the notable products that have been brought into the cancer detection market include biomarkers for breast and cervical cancers. These biomarkers along with imaging technology developed by CytoCore over the last few years can specifically detect any traces of breast or cervical cancer, a feature that is not widely available in the current market. This could lead to an early detection and risk evaluation of breast cancer in women between the age groups of 20 to 40 leading to better outcomes in terms of treatment.

MEDITE is a medical technology company specialized in the development of scientifically advanced products for detection and diagnosis of cancer and related diseases

Targeted at providing an efficient and cost-effective treatment through high specificity, MEDITE’s current and upcoming products will assist in early cancer diagnosis with a higher sensitivity in detecting cancerous and pre-cancerous conditions. This eliminates unnecessary testing procedures and false alarms related to cancer leading to better assessment and cost- effective treatment producing more guaranteed results.

In terms of future prospects, MEDITE plans to continue bringing in new products to the market such as at-home specimen collection kits and cell preservation solutions leading it closer to the goal of being a one-stop supplier in terms of complete laboratory processes. With access to public capital markets due to the merger with CytoCore and joint venture with UNIC Medical of China, MEDITE is working toward automation in anatomic pathology laboratory and cytology systems for tissue biopsy and cell sample imaging. Armed with products manufactured and processed using German engineering, MEDITE envisions to carve a niche for itself in complete anatomic lab solutions, which covers slide processing, digitizing and imaging, image analysis, telepathology and lab management.